Focus: Parkinson's disease at forefront of Bayer bet on cell and gene therapies

Core Viewpoint - Bayer is at the forefront of developing innovative cell and gene therapies for Parkinson's disease, which presents both exciting opportunities and significant risks for CEO Bill Anderson as the company faces patent expirations on its blockbuster drugs [1] Group 1 - Bayer's focus on cell and gene therapies highlights its commitment to pioneering treatments in the biopharmaceutical sector [1] - The development of these therapies is seen as a critical test of CEO Bill Anderson's capabilities in leading the company through a transformative period [1] - The impending patent expirations on key products may impact Bayer's revenue streams, making the success of new therapies even more crucial [1]